We will add recommendations over time.
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year. The latest ...
Tris Pharma has set its sights on an FDA filing for pipeline drug cebranopadol before the end of this year after the drug achieved significant pain relief in abdominoplasty patients in a late ...
In mouse thymocytes, positive regulation of inducible T cell kinase (ITK) membrane recruitment by InsP 4 establishes a feedback loop of phospholipase Cγ1 activation downstream of the T cell ...
On Thursday, Tris Pharma released data from a clinical trial of about 240 people who had undergone bunion removal, a notoriously painful operation. Results showed that, over a two-day period post ...
Tris Pharma has announced positive data from two Phase III trials of cebranopadol, as well as positive data from a human abuse potential (HAP) study to compare the therapy against various opioids.
Braemar’s second-in-command is leaving the company. Tris Simmonds is stepping down from his role as chief operating officer at the UK shipbroker with immediate effect. James Gundy’s Braemar ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback